← All trials
NCT05413356
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Jun 1, 2024
- Completion date
- Jan 1, 2025
- First posted
- Jun 10, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Central South UniversityCollaborator
- Jinhua Central HospitalCollaborator
- Fujian Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Zhejiang Chinese Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityOverall official - principal investigator
- Ningbo No. 1 HospitalCollaborator
- Ningbo UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.